1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK

There is a debate about whether patients (pts) with MSI should receive neoadjuvant chemotherapy. DANTE evaluates perioperative FLOT vs. FLOT/atezolizumab for resectable gastric or GEJ adenocarcinoma. Here, we report preliminary data for the pathological (path) regression in pts with MSI.